CMPX Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.…
Industry Peers
BiotechnologyKey Statistics
About Compass Therapeutics (NASDAQ: CMPX)
›
Compass Therapeutics (NASDAQ: CMPX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 39 employees.
The shares were at 0.7738 USD on 13 November 2026, down 84.2% over 52 weeks. Its 52-week range is 0.6714 USD to 6.880 USD: the price is 88.8% below the high and 15.3% above the low.
Its market capitalisation is 139.35M USD.
Compass Therapeutics reports return on equity of -33.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 153.82M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 4 March 2027.